Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Fund Letter | Matt Burdett, Christian Hoffmann, Brian McMahonThornburg Equity Income Builder Fund | PharmaceuticalsPharmaceuticals | Thornburg Equity Income Builder Fund - MRK Global health care company develops and sells medicines, vaccines, biologic therapies. +22.1% in 1H... | BULL | View Pitch → | |
| Sep 2, 2026 | Fund Letter | Ariel Investments, LLCAriel International Fund | PharmaceuticalsPharmaceuticals | Ariel International Fund - MRK.DE We bought Merck KGaA, a leading life science tools company, based on our conviction that a biopharma spending recovery is underway following a prolonged period of inventory destocking and funding constraints. The inflection is... | NEUTRAL | View Pitch → | |
| Sep 2, 2026 | Fund Letter | Ariel Investments, LLCAriel Global Fund | PharmaceuticalsPharmaceuticals | Ariel Global Fund - MRK.DE We purchased Merck KGaA, a leading life science tools company, based on our conviction that a biopharma spending recovery is underway following a prolonged period of inventory destocking and funding constraints. The inflection is... | NEUTRAL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | Glenn Fortin and Rui CardosoBrown Advisory | PharmaceuticalsPharmaceuticals | Long MRK (Merck & Co.) Merck delivered strong full-year results and conservative guidance that addresses impending patent expirations. Its solid balance... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | David BastianKingdom Capital Advisors | -- | Long AMRK (A-Mark Precious Metals) A-Mark is a highly undervalued bullion dealer that benefits from spikes in precious metals demand during periods of banking sector panic and market volatility. The company operates... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | Harris "Kuppy" KuppermanPraetorian Capital Management | -- | Long AMRK (A-Mark Precious Metals, Inc.) A-Mark supplies both online and local coin shop markets as one of the largest players in online coin brokerage through their JM Bullion, LPM, Silver Gold Bull, Goldline, etc. | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | Harris "Kuppy" KuppermanPraetorian Capital Management | -- | Long AMRK (A-Mark Precious Metals, Inc.) As the world gets increasingly crazy, I believe that people will come to realize that ownership of precious metals, in physical form, as opposed to in a brokerage account, is part of being financially | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | Oldfield Partners Overstone Global Large Cap | PharmaceuticalsPharmaceuticals | Long MRK.DE (Merck) Merck was a new purchase during the quarter. Merck started as... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | David BastianKingdom Capital Advisors | -- | Long AMRK (A-Mark Precious Metals, Inc.) A-Mark delivered strong quarterly profitability and successfully capitalized on banking crisis bullion demand spikes while introducing share buybacks. This shift is... | BULL | View Pitch → | |
| Feb 3, 2026 | Fund Letter | Antipodes Global Value Fund | PharmaceuticalsPharmaceuticals | Antipodes Global Value Fund 2025 Q4 (MRK) Merck rallied amid broader enthusiasm toward the healthcare sector, pushing through its 52-week high. The company was... | BULL | View Pitch → | |
| Feb 3, 2026 | Fund Letter | Antipodes Partners LimitedAntipodes Global Fund | PharmaceuticalsPharmaceuticals | Antipodes Global Fund 2025 Q4 (MRK) Merck rallied, amid broader enthusiasm towards the healthcare sector, pushing through its 52-week high. The company was... | BULL | View Pitch → | |
| Jan 28, 2026 | Fund Letter | Scott LaBreche, Christine CappabiancaImpax US Sustainable Economy Fund | PharmaceuticalsPharmaceuticals | Impax US Sustainable Economy Fund 2025 Q4 (MRK) Merck demonstrates outstanding Corporate Resilience across governance, environmental and social dimensions. The company is... | BULL | View Pitch → | |
| Jan 24, 2026 | Fund Letter | Kathleen A. McCarragher, Blair A. Boyer, Natasha KuhlkinHarbor Capital Appreciation Fund | PharmaceuticalsPharmaceuticals | Harbor Capital Appreciation Fund 2025 Q4 (MRK) We initiated a position in Merck, a global biopharmaceutical company with strengthening product visibility and sustained leadership in oncology. Its flagship immuno-oncology... | BULL | View Pitch → | |
| Jan 8, 2026 | Fund Letter | Scott LaBreche, Christine CappabiancaImpax US Sustainable Economy Fund | PharmaceuticalsPharmaceuticals | Impax US Sustainable Economy Fund 2025 Q2 (MRK) Merck & Co (Health Care, Pharmaceuticals) has a high Corporate Resilience score, and is contributing to a more robust and sustainable health care system through its leading drug and vaccine discovery efforts. The stock's weakness... | BULL | View Pitch → | |
| Dec 4, 2025 | Fund Letter | James Cullen | Newmark Group $NMRK• NASDAQ | Real Estate Management & DevelopmentReal Estate Management & Development | Cullen Small Cap Value Equity 2025 Q2 (NMRK) Newmark Group (NMRK) is a top-tier commercial real estate (CRE) services firm offering a full suite of advisory solutions across investment sales, debt brokerage, leasing, property and facility management, mortgage servicing, and valuation. The company is... | BULL | View Pitch → |
| Nov 28, 2025 | Fund Letter | Bill SmeadSmead Value Fund | PharmaceuticalsPharmaceuticals | Smead Value Fund 2025 Q3 (MRK) R. Horton [DHI] and... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.